MACK Merrimack Pharmaceuticals Inc.

+0.2  (+4%)
Previous Close 5.58
Open 5.63
Price To Book 1.57
Market Cap 77,122,014
Shares 13,342,909
Volume 46,644
Short Ratio
Av. Daily Volume 48,224

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 trial termination announced November 7, 2018.
HER2 negative metastatic breast cancer
Phase 2 data released June 25, 2018 - endpoints not met.
Cancer - front line pancreatic cancer
Phase 2 trial discontinued December 21, 2016 due to poor efficacy.
Cancer - HER2-positive locally advanced or metastatic breast cancer
Approved October 22, 2015.
Cancer - second line pancreatic
Phase 2 trial discontinued due to futility - noted October 19, 2018.
Cancer - Heregulin Positive Non-Small Cell Lung Cancer
Acquired by Ipsen
Cancer - HER2-negative gastric cancer
Acquired by Ipsen
Cancer - front line pancreatic
Announced April 4, 2019 discontinuation of development.
Solid tumors
Poster at ASCO June 2018.
Solid tumors

Latest News

  1. The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering
  2. Merrimack axes remaining staff, execs after selling assets to New York startup
  3. Merrimack Pharmaceuticals Announces Completion of Strategic Review, Preservation of Ipsen Milestones and Special Cash Dividend
  4. Merrimack Reports First Quarter 2019 Financial Results
  5. COMM 2014-UBS2 Mortgage Trust -- Moody's affirms ten classes of COMM 2014-UBS2
  6. SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Merrimack Pharmaceuticals, Inc. - MACK
  7. Merrimack Pharmaceuticals, Inc. (MACK) - Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation
  8. The Merrimack Pharmaceuticals (NASDAQ:MACK) Share Price Is Down 92% So Some Shareholders Are Rather Upset
  9. The Daily Biotech Pulse: Merrimack Pulls The Plug On Early-Stage Trial, Legal Headache For Novartis-Amgen Migraine Partnership
  10. Merrimack shelves another cancer drug, plans more layoffs
  11. Merrimack Discontinues Development of MM-310
  12. Merrimack (MACK) Incurs Narrower-Than-Expected Loss in Q4
  13. Merrimack Reports Fourth Quarter and Full Year 2018 Financial Results
  14. New Research: Key Drivers of Growth for ON Semiconductor, Entegris, Universal, MarineMax, Epizyme, and Merrimack Pharmaceuticals — Factors of Influence, Major Initiatives and Sustained Production
  15. Merrimack (MACK) Stock Up Year to Date: Is a Rebound Likely?
  16. Edited Transcript of MACK earnings conference call or presentation 7-Nov-18 1:30pm GMT
  17. John M. Dineen Appointed to Syneos Health Board of Directors, Named Chairman